Literature DB >> 7640066

Chemotherapy in head and neck cancer.

J P Armand1, C Couteau.   

Abstract

Entities:  

Mesh：

Year:  1995        PMID： 7640066     DOI： 10.1016/0959-8049(95)00124-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  3 in total

1.  Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.

Authors:  Barbara Burtness; Jean P Bourhis; Jan B Vermorken; Kevin J Harrington; Ezra E W Cohen
Journal:  Trials       Date:  2014-11-29       Impact factor: 2.279

2.  Chorioallantoic membrane tumor models highlight the effects of cisplatin compounds in oral carcinoma treatment.

Authors:  Patrizia Sarogni; Ana Katrina Mapanao; Alessandra Gonnelli; Maria Laura Ermini; Sabrina Marchetti; Claudia Kusmic; Fabiola Paiar; Valerio Voliani
Journal:  iScience       Date:  2022-02-24

3.  Systemic therapy strategies for head-neck carcinomas: Current status.

Authors:  Thomas K Hoffmann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.